Subcutaneous or Transvenous Defibrillator Therapy

Abstract Background The subcutaneous implantable cardioverter–defibrillator (ICD) was designed to avoid complications related to the transvenous ICD lead by using an entirely extrathoracic placemen...

[1]  P. Lambiase,et al.  Understanding Outcomes with the S-ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED): Clinical characteristics and perioperative results. , 2019, Heart rhythm.

[2]  A. Auricchio,et al.  Prospective blinded evaluation of a novel sensing methodology designed to reduce inappropriate shocks by the subcutaneous implantable cardioverter-defibrillator. , 2018, Heart rhythm.

[3]  D. Theuns,et al.  Six‐year follow‐up of the initial Dutch subcutaneous implantable cardioverter‐defibrillator cohort: Long‐term complications, replacements, and battery longevity , 2018, Journal of cardiovascular electrophysiology.

[4]  K. Ellenbogen,et al.  Risk Factors and Temporal Trends of Complications Associated With Transvenous Implantable Cardiac Defibrillator Leads , 2018, Journal of the American Heart Association.

[5]  A. Auricchio,et al.  Defibrillator shocks and their effect on objective and subjective patient outcomes: Results of the PainFree SST clinical trial. , 2017, Heart rhythm.

[6]  William J. Bryant,et al.  2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2017, Heart rhythm.

[7]  A. Wilde,et al.  Long-Term Clinical Outcomes of Subcutaneous Versus Transvenous Implantable Defibrillator Therapy. , 2016, Journal of the American College of Cardiology.

[8]  Yang Liu,et al.  Multiple Imputation by Fully Conditional Specification for Dealing with Missing Data in a Large Epidemiologic Study , 2015, International journal of statistics in medical research.

[9]  Pier D. Lambiase,et al.  Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-Year Results From a Pooled Analysis of the IDE Study and EFFORTLESS Registry. , 2015, Journal of the American College of Cardiology.

[10]  Ellen Aagaard Nohr,et al.  Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark , 2013, European heart journal.

[11]  Mark Kremers,et al.  Safety and Efficacy of a Totally Subcutaneous Implantable-Cardioverter Defibrillator , 2013, Circulation.

[12]  A. Moss,et al.  Reduction in inappropriate therapy and mortality through ICD programming. , 2012, The New England journal of medicine.

[13]  L. Jordaens,et al.  Rationale and design of the PRAETORIAN trial: a Prospective, RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable cardioverter-defibrillator therapy. , 2012, American heart journal.

[14]  Alexander H Maass,et al.  An entirely subcutaneous implantable cardioverter-defibrillator. , 2010, The New England journal of medicine.

[15]  D. Mark,et al.  Prognostic importance of defibrillator shocks in patients with heart failure. , 2008, The New England journal of medicine.

[16]  I. V. Van Gelder,et al.  Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. , 2008, Journal of the American College of Cardiology.

[17]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[18]  J. Oss,et al.  PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .

[19]  N Engl,et al.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. , 1997, Circulation.